

ABN 54 117 526 137

Vectus Biosystems Limited Chairman's Address to the 27 November 2024 Annual General Meeting

On 24 May 2024 Vectus sadly reported the passing of its co-founder and Chief Executive Officer, Dr Karen Duggan, who, for 18 years, led the Company in an attempt to meet the challenge of prevention and treatment of cardiovascular fibrosis. The Board's sincere gratitude goes to Karen and the Vectus team for their work during the 2023-24 financial year in moving the Company's lead compound, VB0004, through the important Phase Ia and Ib human trials.

The 2024 year saw Vectus achieve a number of important milestones, commencing with the April 2024 finalisation of the Phase Ib human safety clinical trial in collaboration with the Nucleus Network in Melbourne and Scientia Clinical Research in Sydney, and Syneos Health. No significant adverse events were reported in the Phase Ia or Phase Ib human trials. The Company's lead cardiovascular candidate, VB0004, is supported by a broad portfolio of issued patents. Vectus' strategy is to develop and perform early validation of its drug candidates to the point where they become commercially attractive to potential pharmaceutical partners. The Company's objective is to then partner with one or more companies via a licencing programme, focusing initially on VB0004, together with advancing its other drug candidates A32, A79 and P5 from its extensive drug library. Success in licencing any one of the lead compounds in Vectus' drug library could represent a major uplift in shareholder value and help generate additional opportunities.

The Company's drugs are targeting some of the largest pharmaceutical franchises in the world. Vectus is working closely with C14 Consulting Group, LLC in the USA, who will be joining us today, under its exclusive mandate to lead and manage the programme of potential licencing, or a joint venture, or both, of the Company's portfolio of patented small therapeutic molecules, including the human lead compound VB0004. Vectus and C14 have developed new information documentation that is in line with the needs of a broad range of pharmaceutical companies and potential collaborators. C14 is a highly-regarded consultancy with a global capability.

Fibrotic diseases account for a significant percentage of the world's current mortality rate. I see, in my work as a Radiologist and Clinical Physician, the real need for this new class of drugs, providing substantial social, patient and health economic outcomes. Fibrosis, or scar tissue, is the end point of a whole host of diseases, including high blood pressure, following myocardial infarction, traumatic injury, post infections (such as COVID-19), radiotherapy and silicosis. To have potential drugs, like those in the Company's stable, that can not only stop the growth of scar tissue, but also reverse the fibrosis, is a major development in medicine. One of the many innovations of Vectus has been the successful development of small molecule, orally dosable drugs from the native peptides, into the form most common in today's drug presentations.

<u>Finance</u>

The funds expended by the Company during the last year were largely in connection with the finalisation of the Phase Ia and Ib human clinical trials for VB0004. Cash-on-hand at 31 October 2024 was \$936,000. Vectus has dramatically lowered its operating costs whilst maintaining its intellectual property and patent library, which are now the Company's primary focus in commercialising. I am



pleased to report that engagement with well-known pharmaceutical companies has been expanded and today Martina Molsbergen from C14 will be providing some insight into this process.

Accugen

Accugen is one of Vectus' assets that will be made available to the industry to commercialise, subject to finding suitable licencees. The Accugen technology is aimed at improving the speed and accuracy of measuring the amount of DNA and RNA in samples tested in laboratories.

Conclusion

I take this opportunity to thank the Company's team and its Board for their significant contribution to take Vectus to the point where an expanded commercialisation programme is now underway. Dr Susan Pond, who joined the Board in May 2016 and who retires at the end of this AGM, has been a contributor to this process. We wish Susan well in her retirement.


The Company is currently in discussions in relation to the appointment of an additional Non-Executive Director and Vectus anticipates an announcement in the near term. I take this opportunity to express our sincere thanks to the Company's exceptional advisers that have stepped in to help Vectus through this challenging period. Finally, I thank the Company's shareholders for their support during this exciting and challenging year in Vectus' development. We look forward to the partnership with C14 in advancing the commercialisation of the Company's unique library of first-in-class drug assets and, in parallel, we are committed to the goal of advancing the healthcare of patients around the world and, in doing so, benefiting our stakeholders.

Vectus Biosystems Limited

Ron Shnier Chairman

C14 Consulting Group For the Business of Life Sciences

November 2024
Company Presentation



Martina Molsbergen

CEO, C14 Consulting Group

+34 years of business development, marketing, and entrepreneurial experience including 24 years of business development experience in biotherapeutics and antibodies

Proven corporate development strategy and leadership experience within large and small company settings closing +500 deals and creating over \$5B in transactions



Recipient of 4 Presidents' Awards

Exceptional Knowledge

Broad access to academia and industry

C14 is built on a large pedigree of former industry executives with proven track records of success



Business & Investment Strategy



Deal Making



Scientific Evaluation

Pedigree Team & Access to KOLs



Large team of execs, scouts, heads of R&D, and KOLs (MD, Ph.D.) with +20 years industry experience

Strong competence and technical expertise in protein chemistry and drug discovery/development PhD/MS/MD

C14 Team offers:

- √ High-value
- ✓ Trained Effective and Reliable
- ✓ Cost Saving
- ✓ Efficient

Deal Making Success

Proven Track Record is Core Competence

Out licensing focused ("sell" side), negotiations, transactions and strategic alliance management history

Affiliated with many Societies
Frequent Discovery, Clinical Development,
Investment and Partnering meetings

Recognized as the "go to" source for biologics and representing only **Quality** companies

Plethora of deals spanning discovery, clinical and commercial

Leverage C- level contacts within many companies

Large network spanning the globe



Large Experience Base



Life Science Sectors

Pharmaceuticals
Diagnostics
Immunology
Biologics
Vaccines
Platform Technologies



Therapeutic Areas

Cardiology
CNS
Dermatology
Immunology
Infectious Disease
Oncology
Pain & Inflammatory Disease
Respiratory Disease
Women's Health
Urology



Geographic Experience

North America South America Europe Asia Australia Japan

Strategy Refinement

Work with clients to develop a **blueprint** strategy for optimally positioning & maximizing the value of any deal

Evaluate client's current capabilities and desired goals for future growth; identify competitive strengths, capital needs & exit strategies

Identify partners, clarify preferred models, develop presentations




Specialized in business development & investment strategies for platform technologies & products

Business Development Planning

- **✓** Determine best selling features for differentiation
- √ Target list of potential clients
- ✓ Outreach through existing network/ licensing and scientific meetings/ publications/ sponsorships
- **✓** Competitive intelligence
- ✓ Drive decision making to result in deals
- ✓ Creative deal making required/ showcasing of assets

Generating, Accelerating & Expanding Transactional Opportunit es

- **✓** Sourcing, structuring and executing transactional opportunities
- **✓** Creating optimal deal structures: Licensing, Partnering, M&A
- **Asset acquisition and divestiture**
- **✓** Creating venturing capabilities
- ✓ Corporate formation and structuring
- **✓** Valuation and corporate/asset repositioning
- **✓** Fundraising preparation
- √ Strategic advisory





Appendix

Large Clients































Early/Mid stage Clients












































zacharon







Small & Mid Size Biotech/ Specialty Pharm





















agenus















































Gov't & Non-Gov't Organizations



























Investors













Working With Numerous Investors

- Hercules Technology
- Horizon Technology Finance
- Innovis
- J & J Ventures (JJDC)
- JMP Securities
- JP Morgan
- Lilly Ventures
- Lumira Capital
- MedImmune Ventures
- MPM
- Novartis Bioventure Fund
- Novo Ventures
- Oxford Finance Corp.
- Pacific Growth Equities
- Panorama Capital

- A.M. Pappas & Associate
- ABV
- Accelerator
- Actin Biomed
- Aisling Capital
- Alafi Capital
- Alexandria
- Alix Partners
- Amgen Ventures
- Arch
- Atlas Venture
- Bay City Capital
- Biotechnology Value Fund
- CMEA
- De Novo Ventures
- DiBari Group
- EDB (Singapore)
- EQT
- Flagship Ventures
- Gamma Capital Partners

- Paramount BioCapital
- Paul Capital Partners
- Prospect Venture
 Partners
- Puretech Ventures
- RCT
- Science Futures
- Seven Hills
- SG Cowen
- Soffinova
- SR One
- SV Life Sciences
- SVB
- Thomas McNerney Partners
- TPG Ventures
- USVP
- Versant Ventures

Existing Network Of World Class Institutions & Partners



Recognized Abilities

- Nikkei article 2012
- ✓ Recipient of 2 President's Awards, Kyowa Hakko Kogyo 2005, 2007
- ✓ Nikkei article May 2007
- ✓ BioCentury, "Cracking the Code" April 23, 2012 Vol 20, Number 17, pp A1 of 18.





Solutions for Unmet Medical Needs



Introducing

VECTUS BIOSYSTEMS

Advanced Novel Peptide Therapeutic Treatments for Diseases with High Unmet Needs




Publicly traded ASX:VBS

Established Sydney, AU 2005

Company Highlights

- Robust clinical pipeline of fibrosis treatments for high unmet needs
- Accugen Technology: Next generation discovery engine utilizing epigenetics

Robust VIP Pipeline





Cardiovascular Diseases Represent the Leading Cause of Death Worldwide, Accounting for Nearly 18 Million Deaths Annually

The development of myocardial fibrosis associated with all cardiovascular disease, representing pathological changes that correspond with worsened clinical outcomes

Treatment Challenges Present Large Economic Burden

Heart disease remains the predominant cause of mortality in the United States, accounting for nearly **800,000 deaths** per year.

PRESENTS A CONSIDERABLE ECONOMIC BURDEN



Despite substantial improvements in therapeutic strategies, cardiovascular disease remains the leading cause of death worldwide indicating an urgent need for innovative treatment strategies.



VB0004: Novel, First-In-Class VIP Agonist for Treatment of Myocardial & Renal Fibrosis

Replenishing VIP in Tissue

